Compositions and methods for treating rosacea and acne
View Patent ↗Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.
1. A method for treating acne vulgaris in a subject in need thereof, comprising topically administering to the subject a therapeutically effective amount of a breakable foam obtained from a foamable composition once daily for at least seven consecutive days, wherein the foamable composition comprises:
(a) a hydrophobic vehicle comprising:
(i) about 70% to about 90% by weight of a hydrophobic solvent comprising:
about 50% w/w of soybean oil;
about 16.5% w/w to about 30.7% w/w of coconut oil;
about 3.5% w/w to about 6.5% w/w of cyclomethicone; and
about 1% w/w to about 6% w/w of light mineral oil; and
(ii) about 10% to about 22% by weight of a foamer complex comprising:
about 3.5% w/w of cetostearyl alcohol;
about 2% w/w to about 4% w/w of stearic acid;
about 1.8% w/w to about 3.3% w/w of myristyl alcohol;
about 1% w/w to about 3% w/w of hydrogenated castor oil;
about 1% w/w to about 3% w/w of beeswax;
about 1% w/w to about 2% w/w of stearyl alcohol; and
about 0.5% w/w to about 1.5% w/w of behenyl alcohol;
(iii) minocycline in an amount ranging from about 1% w/w to about 4% w/w; and
(b) a propellant in an amount ranging from about 3% to about 25% w/w; and
wherein the foamable composition does not comprises silicon dioxide (SiO 2 ),
wherein seven days of topical treatment with the breakable foam at the therapeutically effective amount results in a maximum concentration of minocycline in plasma from the subject of about 2 ng/mL, as measured during a 24 hour period following the last topical administration, and
wherein the subject is between 15 years old and 16 years and 11 months old.
2. The method of claim 1 , wherein seven days of topical treatment with the therapeutically effective amount results in a concentration of minocycline in plasma from the subjects of about 1.4 ng/mL to about 3.7 ng/mL, as measured 24 hours after the last topical administration.
3. The method of claim 1 , wherein the area under a concentration-time curve of the amount of the minocycline in the plasma of the subjects is determined during a 24 hour period following the last topical administration.
4. The method of claim 3 , wherein the area under the concentration-time curve of the minocycline in the plasma is about 40.8 ng/mL*hour.